Bellicum Pharmaceuticals, Inc.
NASDAQ: BLCM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David M. Maggio
- Employees
- 13
- Headquarters
- Houston, United States
- IPO year
- 2014
- Market cap
- $778.3K
- Website
- https://www.bellicum.com
Loading BLCM…
Loading profile data…Frequently asked questions about BLCM
What does Bellicum Pharmaceuticals, Inc. (BLCM) do?
Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates curr...
Where does BLCM trade?
Bellicum Pharmaceuticals, Inc. (BLCM) trades on the NASDAQ Capital Market.
What sector is BLCM in?
Bellicum Pharmaceuticals, Inc. (BLCM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Bellicum Pharmaceuticals, Inc.?
David M. Maggio is the chief executive officer of Bellicum Pharmaceuticals, Inc. (BLCM).
Where is Bellicum Pharmaceuticals, Inc. headquartered?
Bellicum Pharmaceuticals, Inc. is headquartered in United States.
Does BLCM pay a dividend?
Bellicum Pharmaceuticals, Inc. (BLCM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BLCM go public?
Bellicum Pharmaceuticals, Inc. (BLCM) completed its initial public offering in 2014.